This early-stage trial tests a vaccine called AV-1959R, designed to prevent Alzheimer's disease by targeting a protein linked to the condition. Sixteen healthy adults aged 40-60 will receive three shots of the vaccine or a placebo over 14 weeks. Researchers will monitor for side …
Phase: PHASE1 • Sponsor: Nuravax, Inc. • Aim: Prevention
Last updated Jun 27, 2026 09:08 UTC